PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.
PAMELA
Clinical Trial Program
PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.
Phase II
Status
Follow up
Tumour subtype:
HR+
Scenario
Adyuvante
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Antonio Llombart, MD, PhD (Hospital Arnau de Vilanova Valencia)
Javier Cortés, MD, PhD (Hospital Universitario Vall d’Hebron)
Aleix Prat, MD, PhD (Hospital Clínic de Barcelona)
Sites
COMPLEJO HOSPITALARIO HOSPITAL “SAN PEDRO DE ALCANTARA”, CONSORCIO HOSPITALARIO PROVINCIAL DE CASTELLON, HOSPITAL CLINIC DE BARCELONA, HOSPITAL CLÍNICO UNIV. SANTIAGO DE COMPOSTELA, HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA, HOSPITAL DE FUENLABRADA, HOSPITAL DE TORREVIEJA, HOSPITAL MUTUA DE TERRASSA, HOSPITAL QUIRON DEXEUS (Instituto Oncológico Dr. Rosell), HOSPITAL RAMON Y CAJAL, HOSPITAL SON ESPASES, HOSPITAL SON LLATZER, HOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA, HOSPITAL UNIVERSITARI LLUIS ALCANYIS DE XATIVA, HOSPITAL UNIVERSITARI SANT JOAN DE REUS, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO CLÍNICO SAN CARLOS, HOSPITAL UNIVERSITARIO INFANTA SOFIA SAN SEBASTIAN DE LOS REYES, HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA, ICO HOSPITALET (DURAN I REYNALS), INSTITUTO VALENCIANO DE ONCOLOGÍA
